Industry committee  Well, Mr. Dearden is correct that there is nothing in the WTO rules or dealing with the WTO that regulates the quality, safety, and efficacy of drugs. From that standpoint, there's no liability. Secondly, as a general proposition, virtually all countries maintain domestic regula

Industry committee  Thank you very much. As you noted, India has considerable capacity. India is facing new challenges as the 2005 patent law amendments take effect, and its newer drugs will fall under patent protection and then be less amenable to large-scale domestic production. India just finish

Industry committee  That is the case. The only WTO theoretical dispute settlement penalty is to request Canada to bring its legislation into compliance with the determination of the dispute settlement panel. There is no penalty; there is no monetary fine. Frankly speaking, I think Canada would gain

Industry committee  Thank you very much, Mr. Masse. It is pretty clear, as a matter of the TRIPS agreement and the August 30 decision, that it is perfectly permissible for Canada to adopt a single-licence solution in which a substantial quantity of drugs is provided over a period of time. There is

Industry committee  But you would like me to wrap up.

Industry committee  Yes, let me just make a couple of points. One, there's nothing at all in the TRIPS agreement or the WTO August 30 decision that restricts a licence that would supply multiple destinations on the basis of a single licence. You would also look at the U.S. legislation that allows fo

Industry committee  All right. Can you hear me?

Industry committee  Good morning. I appreciate the opportunity to appear before the committee regarding the bill to enact proposed changes to the CAMR. I appeared before this committee on March 10, 2004, during what was then consideration of Bill C-9, which, as amended, was ultimately enacted as

Industry committee  We just need to be careful because they're having some trouble with the Kenyan transmission.